Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 2Thoracic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 66Lung Neoplasms 26Small Cell Lung Carcinoma 10Pancreatic Neoplasms 6Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Squamous Cell 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Carcinoma, Pancreatic Ductal 3Adenocarcinoma of Lung 3Sarcoma 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2NSCLC 2Melanoma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Tumor Virus Infections 1

Interventions

Cisplatin 4Fluorouracil 3Oxaliplatin 2Leucovorin 2Hyperthermic Intraperitoneal Chemotherapy 2Cytoreduction Surgical Procedures 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1pembrolizumab 1durvalumab 1cc-486 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Mitomycin 1Ifosfamide 1Gemcitabine 1EC regimen 1Doxorubicin 1CP protocol 1Azacitidine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Albumin-Bound Paclitaxel × Thoracic × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡